These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10950622)

  • 1. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland.
    Ljung R
    Haemophilia; 1999 Jul; 5(4):286-91. PubMed ID: 10950622
    [No Abstract]   [Full Text] [Related]  

  • 2. Creutzfeldt-Jakob disease and haemophilia: prospect at the new millennium.
    Liras A
    Haemophilia; 2000 Nov; 6(6):716-8. PubMed ID: 11122406
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.
    Hermans C; De Moerloose P; Fischer K; Holstein K; Klamroth R; Lambert T; Lavigne-Lissalde G; Perez R; Richards M; Dolan G;
    Haemophilia; 2011 May; 17(3):383-92. PubMed ID: 21323794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding and clotting: new therapies and old issues revisited.
    Lee CA; Aledort LM
    Haemophilia; 2009 Mar; 15(2):592-6. PubMed ID: 19335754
    [No Abstract]   [Full Text] [Related]  

  • 5. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
    Ludlam CA
    Lancet; 1997 Dec; 350(9092):1704. PubMed ID: 9400534
    [No Abstract]   [Full Text] [Related]  

  • 6. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient central venous access device insertion in very young children with severe haemophilia.
    Bensadok H; Maniora M; Théron A; Jeziorski E; Rochette A; Navarro R; Schved JF; Champiat MA; Biron-Andreani C
    Blood Coagul Fibrinolysis; 2020 Oct; 31(7):490-492. PubMed ID: 32941198
    [No Abstract]   [Full Text] [Related]  

  • 8. Partnering to change the world for people with haemophilia: 7th Haemophilia Global Summit, Madrid, Spain 22-24 September 2016.
    Dolan G
    Eur J Haematol; 2017 Oct; 99 Suppl 87():3-9. PubMed ID: 28921738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hazards of prothrombin-complex concentrates in treatment of hemophilia.
    Abildgaard CF
    N Engl J Med; 1981 Mar; 304(11):670-1. PubMed ID: 7453748
    [No Abstract]   [Full Text] [Related]  

  • 10. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 11. Prions and haemophilia: assessment of risk.
    Evatt BL
    Haemophilia; 1998 Jul; 4(4):628-33. PubMed ID: 9873805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 1999 Sep; 5 Suppl 3():25-32. PubMed ID: 10597385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
    Valentino LA; Carcao M; Mathew P; Leissinger CA; Berntorp E; Blanchette V; Escuriola-Ettingshausen C; Ewenstein B; Ewing N; Gringeri A; Hoots WK; Negrier C
    Haemophilia; 2009 Jul; 15(4):959-65. PubMed ID: 19320750
    [No Abstract]   [Full Text] [Related]  

  • 14. Difficult clinical challenges in haemophilia: international experiential perspectives.
    Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
    Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary.
    Petrini P; Chambost H; Nemes L
    Haemophilia; 2004 Oct; 10 Suppl 4():94-6. PubMed ID: 15479379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
    Kumar R; Dunn A; Carcao M
    Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current challenges in the management of hemophilia.
    Bauer KA
    Am J Manag Care; 2015 Mar; 21(6 Suppl):S112-22. PubMed ID: 26168206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation and haemophilia A.
    Lerut JP; Laterre PF; Lavenne-Pardonge E; Donataccio M; Geubel A; Reynaert MS; Otte JB
    J Hepatol; 1995 May; 22(5):583-5. PubMed ID: 7650339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing pattern of care of boys with haemophilia in western European centres.
    Chambost H; Ljung R;
    Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.